Clinical Trial Update: Lung Cancer With Copanlisib and Durvalumab [Phase 1]

View source ↗

Summary

Phase 1 trial update on the combination of copanlisib and durvalumab for non-small cell lung cancer has completed its Phase 1 portion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aliqopa (copanlisib)
• IMFINZI (DURVALUMAB)

Snippet

Sponsor: Zhonglin Hao | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED